THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Jeff Moses, CMO, GATC Health“With the most insightful AI platform in biotech, we are uniquely capable of analyzing human biology to address complex physiological issues,” explains Jeff Moses, CMO, GATC Health. The company’s Multiomic Advanced Technology™ (MAT) platform utilizes advanced artificial intelligence to analyze comprehensive biological datasets (multiomics) to yield the most comprehensive, predictive health analysis available. From these insights, GATC Health can identify ways to greatly reduce or mitigate health risks before they manifest. Multiomics is the study of all the molecules in the human body that contribute to or define biological processes. This includes genomics, proteomics, microbiomics, and metabolomics.
Since the human body is comprised of multiple biological systems that are interdependent, using data collected from only one omic, for instance, genomics is not optimal. By taking into account multiomic data, MAT can essentially create a digital human which helps understand what the targets are for certain disease states and how biomarkers work in that context, thus providing deep insights into human biology.
We are uniquely capable of analyzing human biology and addressing complex physiological issues
Initially, the time taken to analyze the multiomic dataset of an individual took about 165 hours. Today, the same can be completed in under five minutes and in parallel with millions of datasets due to GATC Health’s ability to process data increasing exponentially over the years. GATC Health can make very accurate predictions about health risks to a specific disease state very early. GATC Health is collaborating with leading diabetes researchers in the world to extend the honeymoon period for diabetes by 10-15 years through early disease identification and suggesting proper interventions. Earlier detection will help suggest proper interventions primarily lifestyle changes to stave of the rapid decline of a patient once the disease is triggered.
Moses mentions GATC Health’s partnership with Liquid Biosciences, a healthcare company that was investigating the cause of cocaine addiction or stimulant addiction in general. GATC Health was able to illuminate the biological pathways the client had identified prior in less than eight weeks. GATC Health also discovered three new molecules that the company will be the basis for the treatment of stimulant addiction. These developments have high potential to solve an issue where many others have failed previously.
Currently, GATC Health offers diagnostic products that include viral immunity, health and wellness, depression and anxiety, and medical cannabis. The company plans to launch its diagnostic products for diabetes and cardiac risk in the very near future. GATC Health is also in a period of phenomenal growth with a very deep pipeline of projects both internally and through partners. The company is working on refining its platform to reduce millions of man-hours of clinical work down to days of data processing. GATC Health is committed to accelerating the work of labs, pharmaceuticals, and clinics through its AI-enabled multiomic analysis approach.
Company
GATC Health
Management
Jeff Moses, CMO, GATC Health
Description
One company that is at the forefront of the new medicine arena is GATC Health, a pioneering technology company that is on a mission to leverage individualized genetic data to help predict risks and treatment outcomes, and provide precision medicine that is tailored to each patient’s unique needs. GATC Health helps develop personalized medical analysis and reporting for disease risk, tolerance, complications, and preventions. In addition, the company helps fast-track drug discovery and repurposing. With the most insightful AI platform in biotech, we are uniquely capable of analyzing human biology to address complex physiological issues
GATC Health News
University of California, Irvine, Verifies GATC Health's Ability to Predict Drug Efficacy, Safety and Off-target Effects
IRVINE, Calif., -- GATC Health Corp , a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), has successfully completed two external AI platform validation tests in collaboration with a pharmaceutical science lab at University of California, Irvine's (UCI). UCI specifically designed the tests to independently verify the performance of GATC Health's AI's primary drug screening capabilities and provide unique and detailed insights into drug success risks. The successful outcome of the tests mark a significant milestone in the advancement of AI in drug discovery.
The results provide further validation of the ability of GATC's AI platform to effectively measure safety, efficacy, and off-target effects in early-stage drug candidates, which are key indicators of successful phase 1 and phase 2 clinical trials. The study confirmed, and in some cases exceeded, GATC's own internal retrospective double-blinded analysis completed in September 2023, which successfully demonstrated a true positive rate of 86% and a true negative rate of 84%. This internal study analyzed over 14,000 compounds with known outcomes across hundreds of disease states.
"GATC's ability to predict and measure the likelihood of a potential drug successfully treating a specific disease target and also whether that drug candidate has safety risks will provide pharmaceutical companies and investors with a break-through tool for making billion-dollar decisions," said Dr. Tomas Philipson, former Acting Chairman of the White House Council of Economic Advisers and former senior economic advisor to the Commissioner of the Food and Drug Administration. Dr. Philipson also serves as an advisor to GATC Health.
The company's AI screening process comprises three steps, collectively aimed at predicting and enhancing the efficiency and safety of drug discovery:
Safety Screening: Leveraging AI predictions to screen for toxic, or other negative activation on biological targets, this step is crucial in assessing the safety and potential side effects of a drug molecule.
Efficacy Screening: AI predictions are employed to screen for positive activation on intended and unintended targets using a combination of simulation and reverse docking AI on broad biological targets, playing a key role in assessing the efficacy of a drug molecule, along with a secondary evaluation of side effects.
Optimized Screening: Post-initial screening steps, predictions by the AI are made after the GATC platform and its team have acquired knowledge about the molecules being researched. Additional optimizations lead to results that often outperform blind, verified outcomes from UCI, as reflected in internal studies on AI performance.
The external tests administered by UCI rigorously adhered to GATC Health's screening process, presenting molecules and their activity known only to the UCI lab. GATC received only the chemistry of these molecules before providing predictions to UCI on a predetermined set of biological targets. It is noteworthy that the testing of Optimized Screening was not included in the UCI tests.
"By modeling human systems biology and molecular target activity in unique ways, our platform uncovers non-obvious solutions that accelerate all aspects of drug discovery," said Jayson Uffens, Chief Technical Officer and co-founder of GATC Health. "Having a high degree of confidence in the predicted human outcomes for known and novel compounds allows GATC and our partners to make decisions leading to higher quality and lower risk therapeutics."
Methodology:
Following the delivery of predictions by the GATC platform to UCI, the activation data was shared with GATC as the answer key for the test. The Initial Screening was performed in two separate tests against two sets of AI models in the GATC Platform, resulting in independently verified test results of 91% for the Specificity Test (true positive) and 86% for the Sensitivity Test (true negative). Data used for this independent study consisted of over 4,600 molecules between the two tests.
These successful external tests underscore the reliability of the GATC Platform's screening capabilities, affirming its potential to revolutionize the drug discovery landscape. GATC Health remains committed to advancing AI-driven solutions that expedite and optimize the drug discovery process for the benefit of patients globally.